About us
Driven by passion and curiosity for science, we aim for some of the most urgent but also most complex challenges in drug development.
Our team consists of highly skilled and specialized scientists with different backgrounds. Scientific excellence is both a goal and a demand on ourselves.
"Decades of research have gone into a unique treatment concept for neurodegenerative diseases. Priavoid continues to translate this concept into the development of efficient and safe drugs."
Prof. Dr. Dieter Willbold, Co-Founder
Forschungszentrum Jülich / Sascha Kreklau
Our Network
As is well known, together we are stronger. Priavoid is proud of its network. Our most important partners include the Research Center Jülich (FZJ), Heinrich Heine University (HHU) and Prinnovation, a subsidiary of the German Federal Agency for Disruptive Innovation.
Not only are Forschungszentrum Jülich and Heinrich Heine University the birthplaces of Priavoid. The two institutes Physical Biology (HHU) and Structural Biochemistry (FZJ) are also headed by Prof. Dr. Dieter Willbold, supervisory board member and co-founder of Priavoid. All parties benefit from an intensive scientific exchange and collaboration in specific topics.
Prinnovation GmbH was founded as a subsidiary of the Federal Agency for Disruptive Innovation (SPRIN-D). In 2021, Prinnovation and Priavoid established a research collaboration to implement the further clinical development of our Alzheimer's program PRI-002.
